• 1-Myristoylglycerophosphocholine: Evidence and Limits

  2026-10-06

  1-myristoylglycerophosphocholine, also called 14:0 Lyso-PC, is a defined lysophosphatidylcholine species used in lipid signaling research. A 2024 Respiratory Research study linked LysoPC accumulation from injured alveolar type II epithelial cells with fibroblast activation and experimental pulmonary fibrosis, while implicating an HMGCS2–PPARα–CPT1A/CPT2 pathway. However, the study examined LysoPCs as a class rather than establishing that 14:0 Lyso-PC alone drives the reported effects. This overview compares the evidence, identifies conceptual applications in lipid signaling pathway analysis and smooth muscle research, and defines important limits on interpretation.

• CAMLs in Blood: Phenotype and Clinical Utility

  2026-10-06

  Adams and colleagues report a prospective, multi-institutional evaluation of circulating cancer-associated macrophage-like cells, or CAMLs, as phagocytic polyploid giant cancer cells associated with progression and disease spread. The study’s main contribution is to connect a distinctive circulating cell phenotype with metastatic-niche biology while defining the evidence as clinically promising but observational rather than causally or diagnostically conclusive.

• Dantrolene Sodium Salt in Calcium and DNA Repair Research

  2026-10-05

  Dantrolene sodium salt is best supported as a ryanodine receptor antagonist and calcium-signaling research compound. A 2025 CRISPR screen identified drug-associated shifts in DNA double-strand-break repair, but the supplied study summary does not establish dantrolene as a validated NHEJ, MMEJ, or HDR modulator. This overview compares the evidence, outlines conceptual applications, and defines important limitations.

• Gemcitabine in Cholangiocarcinoma Research

  2026-10-05

  This overview examines Gemcitabine as a DNA synthesis–targeting anticancer compound within cholangiocarcinoma research, with emphasis on the 2025 Nature Communications study linking PDHA1 succinylation, α-ketoglutarate, macrophage antigen presentation, and chemotherapy sensitivity. It distinguishes reported preclinical findings from interpretation and outlines evidence limitations without providing experimental procedures.

• BFH772 VEGFR2 Inhibitor: Product Overview

  2026-10-04

  BFH772 is an APExBIO-listed small-molecule VEGFR2 inhibitor intended for conceptual research on VEGFR2-associated angiogenic signaling. No matched paper evidence was provided, so supplier-reported activity, selectivity, and biological claims remain independently unverified here.

• EPZ5676 and the Translational Logic of DOT1L Inhibition

  2026-10-03

  A source-grounded perspective on EPZ5676, DOT1L biology, MLL-rearranged leukemia research, evidence boundaries, and the strategic value of selective epigenetic probes.

• AAL-993: VEGF Receptor Inhibitor Workflows

  2026-10-02

  AAL-993 enables a focused strategy for connecting VEGFR kinase inhibition with endothelial and tumor phenotypes. This workflow combines target-level potency, angiogenesis assays, and carefully bounded comparisons with the SRC/PI3K/AKT findings reported in glioma research.

• Milk-Derived Vesicle Uptake in Intestinal Organoids

  2026-10-01

  This study develops three porcine intestinal stem cell–based models to examine milk-derived extracellular vesicle uptake in physiologically relevant epithelium. Its central findings are that uptake depends on epithelial polarity, differs among organoid formats, and is sensitive to endocytosis inhibition, while colon-derived models show transcriptional responses associated with stemness and differentiation.

• Neticonazole Hydrochloride: Dual-Use Workflows

  2026-10-01

  Neticonazole Hydrochloride supports two distinct research workflows: fungal growth control through membrane-synthesis disruption and exploratory colorectal cancer research focused on exosome release and apoptosis. This guide translates those activities into practical assay design, formulation handling, and troubleshooting decisions while separating established topical use from preclinical oncology evidence.

• Shenqi Fuzheng Injection in Glioma: SRC/PI3K/AKT

  2026-09-30

  This 2024 Journal of Ethnopharmacology study combines network pharmacology with cellular and mouse experiments to examine how Shenqi Fuzheng injection affects glioma proliferation and migration. Its results implicate SRC/PI3K/AKT signaling, cell-cycle arrest, and epithelial–mesenchymal transition changes, while also showing why these findings remain mechanistic and preclinical rather than clinical proof.

• Chronic Cabozantinib Adaptation in RCC

  2026-09-30

  This study uses quantitative phosphoproteomics to distinguish acute kinase-pathway suppression from chronic signaling adaptation during Cabozantinib exposure in renal cell carcinoma. Its central finding is that prolonged treatment preserves suppression of MET activation-loop phosphorylation while selectively remodeling adhesion- and MAPK-associated networks linked to modest, pattern-specific changes in cellular motility.

• FLT3–TAZ Signaling Drives Drug Resistance in BP-CML

  2026-09-29

  Shin et al. repositioned FLT3 as both a prognostic marker and therapeutic vulnerability in blast-phase chronic myeloid leukemia (BP-CML). Their data connect FLT3 to a JAK–STAT3–TAZ–TEAD–CD36 circuit that promotes resistance to BCR::ABL1 tyrosine kinase inhibitors, while supporting FLT3-directed combinations and ponatinib-based treatment strategies in preclinical models.

• Sorafenib: A Mechanism-to-Assay Research Guide

  2026-09-29

  Sorafenib and BAY-43-9006 connect RAF signaling, VEGFR-2 blockade, and tumor angiogenesis in one versatile cancer biology research tool. This guide translates kinase pharmacology and recent VEGFR-2 inhibitor findings into better assay design, model selection, and data interpretation.

• Auranofin: TrxR Inhibitor for Redox Research

  2026-09-28

  Auranofin is a thioredoxin reductase inhibitor that disrupts cellular redox control and supports apoptosis-focused cancer research. Product-reported benchmarks include nanomolar TrxR inhibition, suppression of Helicobacter pylori growth, and radiosensitization of murine tumor cells under defined experimental conditions.

• BFH772 (VEGFR2 inhibitor): Practical Workflow

  2026-09-28

  BFH772 is a small-molecule VEGFR2 inhibitor for research workflows examining VEGFR2-associated signaling and angiogenesis, including tumor angiogenesis models. Its water insolubility and defined kinase selectivity make it a poor fit for aqueous stock preparation or experiments that require broad-spectrum kinase inhibition.

8136 records 1/543 page Next 12345 下5页 Last page